TENOFOVIR DISOPROXIL FUMARATE = TDF oral

Select language:
On this page

     

    Prescription under medical supervision

     

    Therapeutic action

    • Antiretroviral, HIV nucleotide reverse transcriptase inhibitor 

    Indications

    • HIV infection, in combination with other antiretrovirals
    • Post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP), in combination with lamivudine (3TC) or emtricitabine (FTC)

    Forms and strengths

    • 300 mg tablet, equivalent to 245 mg of tenofovir disoproxil

     

    Also comes in fixed-dosed combinations containing tenofovir for HIV treatment.

    Dosage

    • Child 35 kg and over and adult: 300 mg once daily

    Duration

    • The duration of treatment depends on the efficacy and tolerance of tenofovir.

    Contra-indications, adverse effects, precautions

    • Administer with caution in patients with renal impairment.
    • Monitor renal function. In the event of deterioration of renal function, switch to another antiretroviral.
    • Avoid combination (or monitor renal function in the event of combination) with nephrotoxic drugs: aminoglycosides (e.g. gentamicin, streptomycin), amphotericin B, pentamidine, etc.
    • May cause:
      • gastrointestinal disturbances (nausea, vomiting, diarrhoea, etc.), dizziness, fatigue, skin rash;
      • renal impairment, bone loss (osteoporosis, fractures), pancreatitis.
    • Administer with caution and monitor use with NSAID (addition of nephrotoxic activity).
    • Pregnancy: no contra-indication

    Remarks

    • Tenofovir disoproxil is used alone for the treatment of chronic hepatitis B.

    Storage

     
    –  
     
    –  Below 25 °C